葡萄糖转运蛋白在丁酸钠诱导结肠癌细胞凋亡中的作用

目的观察丁酸钠对结肠肿瘤细胞HT-29葡萄糖转运蛋白(GLUT1～GLUT5)表达的影响以及丁酸钠和不同浓度葡萄糖对bax和bcl-x/l表达的影响,探讨丁酸钠诱导肿瘤细胞凋亡的可能机制。方法2005年4月至12月在武汉大学人民医院应用逆转录-聚合酶链反应(RT-PCR)检测GLUT1～GLUT5mRNA的表达情况。免疫细胞化学法检测bax和bcl-x/l的表达。原位切口末端标记法(Tunel)检测细胞凋亡。结果丁酸钠明显抑制GLUT1和bcl-x/l表达并诱导肿瘤细胞凋亡,但对GLUT2、GLUT3、GLUT5和bax表达影响不大,GLUT4则未被检测出。丁酸钠干预条件下,葡萄糖浓度增加可以明显增加bcl-x/l的表达并降低丁酸钠诱导的细胞凋亡。无丁酸钠干预条件下,葡萄糖浓度变化对细胞凋亡影响很小。结论在HT-29细胞中,丁酸钠能明显降低GLUT1的表达。降低GLUT1的表达与丁酸钠诱导细胞凋亡作用密切相关。     

正电子发射型断层显像在结直肠癌肝转移诊断中的应用

目的 评价正电子发射型断层显像(PET)在结直肠癌术后肝转移诊断中的作用。方法 对18例怀疑结直肠癌术后肝转移的患者和3例怀疑其他疾病的患者进行PET检查，通过与CT比较及手术探查，评价PET在结直肠癌肝转移诊断中的作用。结果 怀疑术后肝转移的18例患者，经PET显像确诊17例，其中14例同时伴有肝脏以外的其他脏器转移(肺转移2例、腹壁转移2例、骨转移1例、腹腔淋巴结转移6例、纵隔淋巴结转移2例、锁骨上淋巴结转移1例)；PET诊断阴性的1例患者，随访1年后仍无瘤存活。3例怀疑其他疾病的患者经PET检查发现有结肠癌伴肝转移。结论 与CT相比，PET对结直肠癌术后肝脏及其他部位转移的敏感度更高，对术后肝转移患者是否选择再次手术具有更好的指导意义。     

骨髓间充质干细胞在丝素蛋白/骨形态发生蛋白中的生物学行为观察

目的 观察丝素蛋白与牛骨形态发生蛋白的载体系统与骨髓间充质干细胞的体外相容性.方法 将多孔丝素蛋白修剪成20×10×5 mm长方体状物,置入6孔板中;将粉状bBMP用PBS液溶解制成2mg/ml混悬液,0.5ml无菌移液管滴定于多孔丝素蛋白上(0.5毫升/个).骨髓间充质干细胞以107/ml接种到载体系统上,复合4小时后加入生长液继续体外培养,每1、4、8天时进行碱性磷酸酶、矿化结节染色观察以及扫描电镜和激光共聚焦显微镜观察;另外同时设立单纯丝素蛋白与细胞复合培养对照组进行观察.结果 倒置显微镜、扫描电镜和共聚焦显微镜下观察到细胞在两种材料上生长形态、活性正常,体外培养24小时时细胞已贴附材料上,呈匍匐状伸展,以后逐渐融合生长,8天时大量细胞成片状攀附在材料表面,并分泌有大量的网状细胞外基质,实验组可见结节状基质生成;碱性磷酸酶、矿化结节染色观察发现实验组细胞碱性磷酸酶和矿化结节染色阳性反应,对照组阴性.结论 丝素蛋白是一种良好细胞外基质材料,也是一种良好生长因子的缓释载体.     

重组人骨形态发生蛋白7的腺相关病毒载体的构建

目的构建重组人骨形态发生蛋白7(hBMP7)的腺相关病毒(AAV)载体。方法通过RT-PCR方法,从HEK293细胞中扩增hBMP7全长cDNA并亚克隆入通用型AAV载体质粒pSNAV。将pSNAV-hBMP7质粒DNA转染BHK-21细胞,筛选出携带hBMP7的AAV载体细胞株—BHK-21细胞。用能表达Rap和Cap的重组1型单纯疱疹病毒HSV1-rc/ΔUL2按MOI=0·1感染BHK-21载体细胞株后收获病毒液,通过氯仿—PEG/NaCl沉淀—氯仿抽提纯化病毒。结果所克隆的hBMP7全长cDNA经测序证实和已知hBMP7序列完全一致。通过用能表达Rap和Cap的重组1型单纯疱疹病毒HSV1-rc/ΔUL2感染携带hBMP7基因的AAV载体细胞株BHK-21细胞的方法获得了滴度为2×1012vg/ml、纯度达99%的重组人骨形态发生蛋白7的腺相关病毒载体(AAV-hBMP7)。结论RT-PCR方法从HEK293细胞中扩增克隆hBMP全长cDNA是一种有效可行的方法。成功地构建了高滴度、高纯度的AAV-hBMP7载体,为进一步体内及体外研究基因治疗促进骨愈合提供了有力的工具。     

小肠吸收胆固醇的分子生物学研究进展

胆固醇通过分布于十二指肠和近段空肠黏膜上皮细胞刷状缘膜的Niemann—Pick C1样蛋白1摄取，ATP结合盒G5、G8抑制小肠对胆固醇的摄取过程。进入上皮细胞的胆固醇大多数被乙酰辅酶A，胆固醇转乙酰基酶2酯化，随后通过组装形成乳糜微粒，经淋巴管进入血循环；另一部分胆固醇则以未酯化形式直接进入血循环形成高密度脂蛋白颗粒。这些过程受核受体——肝脏X受体的调控。年龄、性别、黏膜屏障和小肠传输速度也影响胆固醇的吸收。     

曲美他嗪联合阿托伐他汀治疗原发性高血压伴阵发性心房颤动的疗效观察

Objective To study the efficacy of trimctazidine combined with atorvastatin for primary hypertension with paroxysmal auricular fibrillation,and its effects on LAD and CRP. Methods 160 patients of pri-mary hypertension with paroxysmal auricular fibrillation were randomly divided into 4 groups. Forty patients were treated with amiodarone (control group),600 mg/d for the first week,400 mg/d for the second week and 200 mg/d later;40 patients were treated with atorvastatin (20 mg/d,3 times per day) in addition to amiodarone (the atorvasat-in group);40 patients were treated with trimetazidine (20 mg/d,3 times per day) in addition to armiodarone (the trimetazidine group);40 patients were treated with combination of trimetazidine and atorvastatin in addition to amiod-atone (the combination group),and the dose was the same as the above groups. The treatment was started within 24 hours of recovering from paroxysmal auricular fibrillation and lasted for 1 year. Results After 1 year there was 1 pa-the control group,and 62.5% (25/40) for the atorvasatin group,64.1% (25/39) for the trimetazidine group,and 84.6% (33/39) for the combination group. Compared to the control group,the effective rate of the 3 treatment groups were all significantly higher (X2=4.56、5.13、17.55,P<0.05). The effective rate of the combination group was significantly higher than that of the atorvasatin group and the trimetazidine group (X2=4.95、4.30,P<0.05),and there was no significant difference of effective rate between the atorvasatin group and the trimetazidine group(X2= >0.05). After treatment LAD was (40.96+1.81) mm in the control group,(38.65±1.90) mm in the atorvasatin group,(39.15±1.85)mm in the trimetazidine group,and (37.22±1.74) mm in the combination group. LAD of the 3 treatment groups were all significantly different from the control group(F=3.42,P<0.05). LAD of the combina-tion group was significantly smaller than that of the atorvasatin group and the trimetazidine group (P<0.05),and there was no significant difference of the LAD between the atorvasatin group and the trimetazidine group(P>0.05). There was no significant difference between the 4 groups on CRP before treatment (F=0.96,P>0.05). After treat-ment CRP was (8.85±1.45) mg/L in the control group,(5.96±1.26) mg/L in the atorvasatin group,(6.81± 1.37) mg/L in the trimetazidine group,and (3.75±1.15) mg/L in the combination group. CRP of the 3 treatment groups were all significantly different from the control group (F=3.63,P<0.05). CRP of the combination group was significantly lower than that of the atorvasatin group and the trimetazidine group (P<0.05),and there was no signif-icant difference of CRP between the atorvasatin group and the trimetazidine group (P>0.05). Conclusion The treatment with trmetazidine combined with atorvastatin could prevent recurrence of paroxysmal auricular fibrillation though anti-inflammatory and inhibiting the remodeling of left atrial.     

本刊被国际检索系统美国《化学文摘》收录

背景与目 的光动力学疗法（PDT）是对化疗和放疗已产生耐药的肿瘤的一种替代疗法。该方法主要通过激光照射光敏剂产生活性氧，继而杀死肿瘤细胞。有研究表明抑癌蛋白P53能使人类某些肿瘤细胞对PDT治疗更加敏感。但是，目前仍然没有直接的证据来证明这一观点。本研究旨在探讨肿瘤细胞中原卟啉Ⅸ（protoporphyrin Ⅸ，PpⅨ）和野生型P53蛋白的相互作用，及PpⅨ和PpⅨ—PDT诱导人结肠癌细胞发生死亡与P53蛋白的相关性。     

慢性移植物肾病治疗策略

本文主要阐述了免疫抑制剂应用，防治高血压，限制蛋白饮食，以及降低血脂、抗凝剂与中医中药在防治慢性移植物肾病中的作用。     

特发性血小板减少性紫癜患者B淋巴细胞的特征

为了探讨特发性血小板减少性紫癜(ITP)的发病机制，我们对50例ITP患者(正常对照30例)外周血总B淋巴细胞、CD5^ B淋巴细胞的数量，B淋巴细胞Fas蛋白、FasL蛋白，CD40^ 、CD80^ 和CD86^ 表达率，胞浆内凋亡蛋白bcl-2的表达水平进行了测定。     

氯沙坦通过下调单核细胞趋化蛋白1受体表达抑制单核细胞活化

目的探讨血管紧张素Ⅱ对单核细胞趋化蛋白1受体CCR2表达的影响及氯沙坦的干预作用。方法人单核细胞株与血管紧张素Ⅱ(10-7mol/L)孵育,加或不加氯沙坦(10-7、10-6和10-5mol/L),检测上清液中单核细胞趋化蛋白1水平、单核和内皮细胞粘附情况以及CCR2mRNA的表达。结果与对照组比较,血管紧张素Ⅱ明显增加单核细胞培养上清液中单核细胞趋化蛋白1水平(26.46±3.58ng/L比10.56±2.34ng/L,P<0.01),增加单核内皮细胞间粘附(596±27比268±16,P<0.01)。血管紧张素Ⅱ刺激细胞后明显上调CCR2mRNA表达,氯沙坦能显著抑制血管紧张素Ⅱ的作用,降低单核细胞趋化蛋白1的水平,减少单核内皮细胞间粘附,下调CCR2 mRNA表达。结论氯沙坦通过下调单核细胞趋化蛋白1受体CCR2基因表达抑制单核细胞活化。